PetVivo (PETV) Status Update summary

Shareholder meeting and board updates

• Definitive 14(c) information statement approved election of seven directors and ratified the appointment of Assurance Dimensions, Inc. as the independent auditor for fiscal year ending March 31, 2025.

• Majority voting power approved these actions by written consent, bypassing a formal meeting.

Product and market overview

• Spryng with OsteoCushion technology is a veterinary medical device targeting osteoarthritis in dogs, cats, and horses, addressing the root cause rather than just symptoms.

• Product is naturally derived, requires no FDA approval, and is distributed through major veterinary channels.

• Over 10,000 animals treated with low adverse event rates; strong IP portfolio with 12 U.S. and 9 foreign patents.

Clinical and commercial progress

• Multiple pilot and tolerance studies show significant improvement in canine hip dysplasia and CCL disease, with further double-blind studies underway and results expected in 2025.

• Spryng is now included in key veterinary manuals and protocols, with growing recognition and use in major universities and clinics.

• Expanded sales team and distribution, targeting dramatic sales growth and new territories in fiscal 2026.